Northland Securities reissued their buy rating on shares of Evgen Pharma PLC (LON:EVG) in a research report released on Thursday. The firm currently has a GBX 97 ($1.27) price objective on the stock.

Separately, Beaufort Securities reissued a speculative buy rating on shares of Evgen Pharma PLC in a report on Wednesday, June 1st.

Evgen Pharma PLC (LON:EVG) opened at 30.00 on Thursday. The firm’s market capitalization is GBX 21.94 million. Evgen Pharma PLC has a one year low of GBX 14.50 and a one year high of GBX 45.00. The company has a 50-day moving average of GBX 25.48 and a 200 day moving average of GBX 20.58.

About Evgen Pharma PLC

Evgen Pharma PLC is a United Kingdom-based clinical-stage drug development company. The Company’s lead programs are focused on the treatment of cancers, such as breast and prostate cancer, and neurological conditions, such as subarachnoid hemorrhage. The Company has completed Phase I trials for its development product, SFX-01.

Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.